glp-1 agonist history Historical timeline of biology, receptor discovery, and Discovery of GLP-1–Based Drugs for
Description
Lilly currently leads with roughly 60% market share, compared with Novo's 39% as of the first quarter
& Goke, B
Beyond glucose control, GLP-1 significantly affects satiety and gastric function
Having different dosing options (or different assets with varying degrees of efficacy) may give manufacturers an edge to potentially allow for dosing flexibility for weight maintenance
Triplehormone-receptor agonist retatrutide for obesity A phase 2 trial
Approximately 50% of the global population carries H
